Clinical Trials
41 trialsABBY
Abramson Cancer Center at Penn Medicine
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
I-SPY
QuantumLeap Healthcare Collaborative
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
FAIM
Royal Marsden NHS Foundation Trust
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
ABBICAR
Universitaire Ziekenhuizen KU Leuven
CARABELA
Spanish Breast Cancer Research Group
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
MiRaDoR
MedSIR
VIOLET
Mario Negri Institute for Pharmacological Research
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
Dana-Farber Cancer Institute
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
Fudan University
Next MONARCH 1
Eli Lilly and Company
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
The Methodist Hospital Research Institute
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
ARCHE
Nagoya City University
ABIGAIL
MedSIR
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Mayo Clinic
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Jonsson Comprehensive Cancer Center
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
HERMIONE-7
University of Milano Bicocca
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Duke University
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
Neo-AGILE
Fondazione Oncotech
ELAINEII
Sermonix Pharmaceuticals Inc.
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
monarcHER
Eli Lilly and Company
abemaSNF1/3
Fudan University
A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer
Eli Lilly and Company
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
University of California, Irvine
ORACLE-RIPA
National Taiwan University Hospital
T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer
Academic and Community Cancer Research United
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Eli Lilly and Company
neoMONARCH
Eli Lilly and Company
MONARCH 1
Eli Lilly and Company
ABC-POP
Gustave Roussy, Cancer Campus, Grand Paris